Table 2.
Systemic treatment choices in patients diagnosed with HR+/HER2− breast cancer and triple-negative breast cancer, total and according to risk profile
| Systemic treatment | Total HR+/HER2− BC population (n = 87 455) | Low-risk HR+/HER2− BC population (n = 44 078) | Intermediate-risk HR+/HER2− BC population (n = 28 452) | High-risk HR+/HER2− BC population (n = 11 285) | Total TNBC population (n = 12 689) |
|---|---|---|---|---|---|
| Endocrine therapy, n (%) | 55 439 (63) | 16 577 (38) | 25 681 (90) | 10 584 (94) | NA |
| Neoadjuvant | 2725 (3) | 314 (1) | 1418 (5) | 599 (5) | NA |
| Adjuvant | 55 300 (63) | 16 535 (38) | 25 615 (90) | 10 568 (94) | NA |
| Chemotherapy, n (%) | 26 737 (31) | 3130 (7) | 13 343 (47) | 8222 (73) | 8809 (69) |
| Neoadjuvant | 9321 (11) | 233 (1) | 3770 (13) | 3544 (31) | 4445 (35) |
| Adjuvant | 17 900 (21) | 2901 (7) | 9711 (34) | 4985 (44) | 5298 (42) |
| Endocrine therapy and chemotherapy, n (%) | 25 316 (29) | 2960 (7) | 12 620 (44) | 7812 (69) | NA |
| No systemic therapy, n (%) | 30 593 (35) | 27 329 (62) | 2048 (7) | 291 (3) | 3836 (30) |
HR+/HER2− BC, hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer; NA, not applicable; TNBC, triple-negative breast cancer.